Get the Stockscreener App
3.25
4.50%
0.14
Pre-market:
3.49
0.24
+7.38%
Elutia Inc stock is traded at $3.25, with a volume of 41,117.
It is up +4.50% in the last 24 hours and up +13.64% over the past month.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
See More
Previous Close:
$3.11
Open:
$3.105
24h Volume:
41,117
Relative Volume:
1.02
Market Cap:
$130.27M
Revenue:
$24.99M
Net Income/Loss:
$-65.24M
P/E Ratio:
-1.1364
EPS:
-2.86
Net Cash Flow:
$-21.27M
1W Performance:
+27.45%
1M Performance:
+13.64%
6M Performance:
-24.42%
1Y Performance:
+8.70%
1-Day Range:
$3.08
$3.25
1-Week Range:
$2.4501
$3.25
52-Week Range:
$2.28
$5.24
Elutia Inc Stock (ELUT) Company Profile
Name
Elutia Inc
Sector
Industry
Phone
240-247-1143
Address
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
3.25 | 130.27M | 24.99M | -65.24M | -21.27M | -2.86 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-02-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-02-20 | Initiated | Cowen | Outperform |
| Nov-02-20 | Initiated | Piper Sandler | Overweight |
| Nov-02-20 | Initiated | Truist | Buy |
Elutia Inc Stock (ELUT) Latest News
HighCape Capital buys $1.05 million in Elutia Inc. stock By Investing.com - Investing.com South Africa
HighCape Capital buys $1.05 million in Elutia Inc. stock - Investing.com India
Elutia Inc. sees $1.05 million stock purchase by HighCape entities - Investing.com Australia
Elutia Inc. Reports Strong Demand for EluPro™ - TipRanks
ELUTIA INC. SEC 10-K Report - TradingView
Earnings call transcript: Elutia Q4 2024 misses forecasts, stock drops By Investing.com - Investing.com Australia
Elutia’s (ELUT) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
Earnings call transcript: Elutia Q4 2024 misses forecasts, stock drops - Investing.com India
Elutia Inc (ELUT) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Product Growth ... - Yahoo Finance
Elutia Inc (ELUT) Q4 2024 Earnings Call Highlights: Strategic Pa - GuruFocus.com
Elutia Inc (ELUT) Reports Q4 2024 Earnings: EPS of -$0.25 Meets - GuruFocus.com
Elutia reports Q4 EPS (26c) vs. (40c) last year - TipRanks
Elutia Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out - The Manila Times
Can Elutia's EluPro Success Overcome Broader Revenue Challenges? Q4 Earnings Deep Dive - StockTitan
Earnings To Watch: Elutia Inc (ELUT) Reports Q4 2024 Result - GuruFocus.com
Elutia Inc. (NASDAQ:ELUT) Short Interest Update - Defense World
Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025 - The Manila Times
Can This Drug-Eluting Biomatrix Leader Maintain Its Innovation Momentum? Q4 Results Coming - StockTitan
Elutia Inc. secures $15 million through stock and warrant sale By Investing.com - Investing.com Nigeria
Elutia’s $15 Million Registered Direct Offering - Global Legal Chronicle
Private equity firms are Elutia Inc.'s (NASDAQ:ELUT) biggest owners and were hit after market cap dropped US$3.9m - Yahoo Finance
Elutia (NASDAQ: ELUT) Preparing to Release 2024 Financial Results - Defense World
Aziyo Biologics Announces Strategic Financial Offering - TipRanks
Elutia Inc. (NASDAQ:ELUT) Short Interest Up 29.8% in January - MarketBeat
Elutia launches $15M securities offering - MSN
Elutia Inc. secures $15 million through stock and warrant sale - Investing.com India
Elutia Inc. reports mixed preliminary 2024 financial results By Investing.com - Investing.com Australia
Elutia Announces $15.0 Million Registered Direct Offering - citybiz
Elutia Inc. reports mixed preliminary 2024 financial results - Investing.com India
Elutia to Raise Roughly $15 Million Through Registered Direct Offering -February 03, 2025 at 09:09 am EST - Marketscreener.com
Elutia Inc. Provides Sales Guidance for the Year Ended December 31, 2024 -February 03, 2025 at 06:08 am EST - Marketscreener.com
SEC Form 424B5 filed by Elutia Inc. - Quantisnow
Cantor Fitzgerald Raises Earnings Estimates for Elutia - Defense World
Cantor Fitzgerald Forecasts Increased Earnings for Elutia - MarketBeat
Cantor Fitzgerald Predicts Elutia FY2025 Earnings - Defense World
Elutia announces full U.S. commercial launch of EluPro - Yahoo Finance
Elutia Inc. Announces Full Launch of EluPro? Following Strong Initial Demand -January 14, 2025 at 08:00 am EST - Marketscreener.com
Elutia Announces Full Launch of EluPro™ Following Strong Initial Demand - The Manila Times
Elutia Inc. (NASDAQ:ELUT) Stock Position Lifted by Geode Capital Management LLC - Defense World
Elutia secures deal to supply antibiotic bioenvelope By Investing.com - Investing.com Australia
Elutia Inc Stock (ELUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):